Fig. 2: Resistance to vemurafenib in PTC was related to upregulated Ref-1 expression. | Cell Death & Disease

Fig. 2: Resistance to vemurafenib in PTC was related to upregulated Ref-1 expression.

From: Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib

Fig. 2

A Analysis of data from the TCGA database for Ref-1 mRNA expression levels in BRAFwt and BRAFmut PTC (upper) and melanoma (bottom) cases. B Correlation analysis of Ref-1 and MAPK pathway targeting genes expression in PTC (upper) and melanoma (bottom) cases based on the TCGA database. C Analysis of data from the TCGA database for NOX4 mRNA expression levels in BRAFwt and BRAFmut PTC (upper) and melanoma (bottom) cases. D Correlation analysis of Ref-1 and NOX4 mRNA expression levels in PTC (upper) and melanoma (bottom) cases based on the TCGA database. E Vemurafenib IC50 detection by a CCK-8 assay in BCPAP, K-1, and A375 cells. F Cell proliferation ability detection by a CCK-8 assay after vemurafenib (10 μM) and E3330 (different concentration gradient) pretreatment in BCPAP and K-1 cells. G Vemurafenib IC50 detection after E3330 pretreatment by a CCK-8 assay in BCPAP and K-1 cells. *P < 0.05, **P < 0.01. ***P < 0.001.

Back to article page